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In the past two decades, molecular biology research has 
revealed the intimate mechanisms of epidemiologically 
significant  diseases,  such  as  cancer,  infections  and 
immunological  disorders.  As  the  next  step  beyond 
seeking  the  mechanisms  involved,  scientists  are  now 
increasingly making it possible to regulate human bio­
logical reactions. In recent years, there have been break­
throughs in genetic engineering related to the inventory 
and  methods  necessary  to  physically  construct  and 
assemble  biomolecular  parts,  such  as  synthetic  RNA­
based regulatory systems [1]. Synthetic biology relies on 
the  engineering  of  biological  systems  that  perform 
human­defined  functions  and  on  the  synthesis  of 
complex, biologically based systems that show functions 
that  do  not  exist  in  nature.  Despite  the  possible 
advantages for clinical applications, more work remains 
to  be  done  to  elucidate  the  principles  of  biological 
design,  and  to  overcome  the  scientific  and  technical 
challenges  in  designing  and  building  more  effective 
systems  that  are  harmless  to  humans  and  therefore 
useful for clinical applications.
A recent study by Chen et al. [2] has produced a signi  fi­
cant  advance  in  solving  such  issues  and  therefore 
potentially bridging the gap between the bench and the 
bedside for synthetic RNA­based regulatory systems. The 
authors [2] developed a modular device composed of a 
sensor (an aptamer) and a gene­regulatory component (a 
hammerhead ribozyme) and tested its ability to affect the 
expression of cytokines important for the function of T­
lymphocytes in mouse and human systems.
Why is this work [2] significant? First, it represents the 
logical  continuation  of  years  of  experimental  work 
performed by the same group, coming from a team that 
understands the way a synthetic RNA­based regulatory 
system works and its immediate practical applications. In 
fact, in a previous study [3], also published in Proceedings 
of the National Academy of Sciences of the United States 
of America, the authors were the first to develop and set 
up  universal  RNA­based  regulatory  platforms,  called 
ribozyme switches, by using engineering design princi­
ples. In the present report [2], the authors expanded the 
advantages of such biomodular platforms to a broader 
range  of  applications.  They  were  able  to  do  so  by  the 
reliable de novo construction of modular, portable and 
scalable control systems that can achieve flexible regu  la­
tory  properties,  such  as  up­  and  down­regulation  of 
target  expression  levels  and  tuning  of  regulatory  res­
ponses to fit application­specific performance requirements.
Second,  the  authors  [2]  applied  the  synthetic  RNA 
regulatory device to a significant medical issue, the use of 
adoptive cell transfer (ACT) [4]. The ACT strategy uses 
T­cell­based cytotoxic responses to attack malignant cells 
(or  any  other  types  of  abnormal  cells)  that  escape  the 
body’s natural surveillance by using T cells that have a 
natural or genetically engineered reactivity to a patient’s 
cancer  cells.  For  this  purpose,  T  cells  have  first  to  be 
Abstract
Synthetic RNA-based regulatory systems are used 
to program higher-level biological functions that 
could be exploited, among many applications, for in 
vivo diagnostic and therapeutic applications. Chen 
and colleagues have recently reported a significant 
technological advance by producing an RNA modular 
device based on a hammerhead ribozyme and 
successfully tested its ability to control the proliferation 
of mammalian T lymphocytes. Like all exciting research, 
this work raises a lot of significant questions. How 
quickly will such knowledge be translated into clinical 
practice? How efficient will this system be in human 
clinical trials involving adaptive T-cell therapy? We 
discuss the possible advantages of using such new 
technologies for specific therapeutic applications.
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tumor­specific antigen, then expanded and made more 
effective in vitro, and finally adoptively transferred into a 
cancer patient. However, the clinical efficacy of ACT, so 
far, has been limited. There are many reasons for this, and 
insufficient persistence and reactivation of infused T cells 
are  among  the  main  ones.  Conventional  strategies  for 
enhancing the persistence of transferred T cells include 
ablation of all white blood cells (myeloablative methods), 
such as total body irradiation and administration of toxic 
levels  of  interleukin  (IL)­2.  However,  myeloablation  is 
associated  with  considerable  morbidity,  caused  by 
decreased immune response and increased risk of infec­
tion [5]. Therefore, safer and more effective thera  peutic 
strategies are yet to be discovered.
Chen et al. [2] report on a synthetic RNA regulatory 
system, which marks a new era in adoptive T­cell therapy 
because of the increase in the amount and survival of 
infused T cells found with this system. Their system for 
the control of mammalian T­cell proliferation is based on 
a  platform  of  assembled  RNA  devices  formed  by  a 
modular  sensor  (aptamer)  and  a  gene­regulatory 
(hammer  head  ribozyme)  component.  This  device  con­
verts  a  small­molecule  input  to  an  increased  gene 
expression  output,  in  this  particular  case  cytokine 
production.  In  more  detail,  the  authors  [2]  fused  a 
theophylline  ribozyme  switch  to  the  3’  untranslated 
region  of  a  tri­functional  transgene  (cd19-tk-t2a-il15) 
encoding IL­15 (potent survival/proliferative cytokine of 
T  cells),  mutant  HSV­1  thymidine  kinase  (acting  as  a 
reporter  and  as  a  suicide  protein  in  the  presence  of 
ganciclovir) and CD19 (a marker for fluorescence­activated 
cell sorting and immuno  magnetic selection). Using this 
system, they could strictly measure (by monitoring the 
expression  of  CD19)  and  control  (by  modulating  the 
levels  of  the  input  molecule)  the  biological  response 
(cell proliferation/viability).
In addition to all the in vitro evidence, the authors [2] 
demonstrated  that  this  system  worked  in  vivo  and 
effectively modulated the T­cell growth rate in mice in 
response to theophylline administration. The growth rate 
was increased to 32% in the presence of theophylline over 
a  14  day  study  in  mice.  They  further  investigated  its 
possible  clinical  application  by  transducing  primary 
human central memory T cells with this system. In vitro 
results showed that the population of live central memory 
T cells increased by 24% and that apoptotic cell popu­
lation  was  decreased  by  54%  in  the  theophylline­
responsive system [2].
Finally,  the  presented  gene  regulatory  system  [2] 
showed significant advantages over available gene regu­
la  tory  techniques  (synthetic  inducible  promoters);  in 
par  ticular,  it  provides  a  wide  range  of  flexibility  for 
clinical  settings.  Firstly,  the  ribozyme  switches  can  be 
easily  programmed  to  respond  to  different  drug 
molecules.  Secondly,  the  system  can  be  stringently 
controlled and finely tuned by adding additional drug­
responsive  ribozyme  switches  (up  to  four),  therefore 
achieving  lower  basal  gene  expression  levels.  Thirdly, 
this  system  shows  tight  drug­mediated  regulation  of 
growth over an extended time period. Taking all these 
features into consideration, it is feasible that this new 
synthetic  RNA­based  regulatory  system  could  have 
straightforward clinical utility.
It  is  likely  that  combining  this  new  modular  device 
framework with upcoming advances in synthetic biology 
will  strongly  support  the  tailoring  of  RNA­based 
regulatory  systems  to  diverse  applications  in  various 
clinical and laboratory environments. Yet applying these 
RNA­based regulatory systems in clinical practice may 
still require more time. In addition, there are many other 
factors that limit the use of adoptive T­cell therapy for 
cancer.  For  example,  the  failure  of  adoptive  immuno­
therapy  against  cancers  lies  in  the  absence  of  tumor­
specific sources of T cells [6]. If such obstacles are not 
overcome, efficacy of these systems will be significantly 
limited in clinical practice. Also, recent data support the 
combined roles of protein­coding genes and non­coding 
RNAs,  such  as  microRNAs,  in  the  pathogenesis  of 
frequent diseases (such as cancer, immune and cardiac 
disorders)  [7].  One  question  for  the  future  is  whether 
such  devices  can  be  adapted  for  the  regulation  of  the 
functions  of  non­coding  RNAs  and  microRNAs.  The 
published research is good news, but it would be better 
to hold our cheers until the clinical trials are successfully 
completed, which we hope will be in the near future.
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